Trident Texofab

Why is Trident Texofab Ltd falling/rising?

As of 23-Jun, Trident Texofab Ltd's stock price is declining, currently at 39.00, down 1.79%. The stock has significantly underperformed over various periods, with a year-to-date decline of 83.34% and diminished investor interest, contributing to its bearish trend.

As of 23-Jun, Trident Texofab Ltd's stock price is falling, currently at 39.00, reflecting a decrease of 0.71 or 1.79%. The stock has been on a downward trend, having underperformed its sector by 0.89% today and experiencing consecutive falls over the last two days, totaling a decline of 2.52%. <BR><BR>In terms of performance metrics, the stock has shown significant underperformance over various periods, with a year-to-date decline of 83.34% compared to a 10.58% drop in the Sensex. Over the past year, the stock has generated returns of -81.84%, while its profits have decreased by 27.5%. Additionally, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend.<BR><BR>Investor participation has also diminished, with delivery volume dropping by 81.26% against the five-day average. This lack of interest from investors, combined with the company's weak long-term fundamentals—such as operating losses and a high debt-to-EBITDA ratio—further contributes to the stock's decline. Overall, the combination of poor financial performance, declining investor interest, and unfavorable comparisons to benchmarks has led to the stock's falling price.

Which are the latest news on Trident Texofab?

What does Trident Texofab do?

Trident Texofab Ltd is a Micro Cap company in the Garments & Apparels industry, incorporated in 2008 and converted to a Public Limited Company in 2017, with recent quarterly net sales of 34 Cr and a net profit of -2 Cr as of March 2026. The company has a market cap of INR 54 Cr and key financial metrics include a P/E ratio of 30.00 and a debt-equity ratio of 0.66.

Overview:<BR>Trident Texofab Ltd operates in the Garments & Apparels industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Trident Texofab Ltd was originally incorporated as a Private Limited Company on September 05, 2008, and later converted into a Public Limited Company on June 06, 2017. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 34 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: -2 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 54 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.66<BR>- Return on Equity: 3.27%<BR>- Price to Book: 0.95<BR><BR>Contact Details:<BR>Address: 2004 2nd Flr North Extension, Nodh 4/1650 Sahara Darwaja Surat Gujarat : 395003<BR>Tel: 91-261-2451284/2451274<BR>Email: info@tridentexofab.com<BR>Website: http://www.tridenttexofab.com

How big is Trident Texofab?

As of 10th June, Trident Texofab Ltd has a market capitalization of 54.00 Cr, with recent net sales of 118.02 Cr and a net profit of 0.71 Cr. Shareholder's funds are 47.24 Cr and total assets amount to 100.58 Cr.

As of 10th June, Trident Texofab Ltd has a market capitalization of 54.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Trident Texofab reported Net Sales of 118.02 Cr and a Net Profit of 0.71 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 47.24 Cr and Total Assets of 100.58 Cr.

Who are in the management team of Trident Texofab?

The management team of Trident Texofab includes Hardik J Desai (Chairman & Managing Director), Chetan C Jariwala (Whole-time Director), and several directors and independent directors, totaling 11 members responsible for the company's strategic direction.

The management team of Trident Texofab includes the following individuals:<BR><BR>1. **Hardik J Desai** - Chairman & Managing Director<BR>2. **Chetan C Jariwala** - Whole-time Director<BR>3. **Maniya H Desai** - Director<BR>4. **Deepak P Gandhi** - Director<BR>5. **Natasha F Dsouza** - Independent Director<BR>6. **Ankita Jignesh Saraiya** - Independent Director<BR>7. **Vrusti B Patel** - Additional Independent Director<BR>8. **Manish Dhirajlaa Halwawala** - Additional Director<BR>9. **Rushi Hemantkumar Jagani** - Director<BR>10. **Mehul N Amareliya** - Company Secretary<BR>11. **Sanju Patel** - Company Secretary<BR><BR>This team is responsible for the strategic direction and management of the company.

Who are the peers of the Trident Texofab?

Trident Texofab's peers include Bang Overseas, Parmeshwari Silk, Shekhawati Inds, Shubham Polyspin, Vinny Overseas, SVP Global, Gujarat Cotex, and Nandani Creation. Trident Texofab has below-average growth and management risk, with a significant negative 1-year return of -81.70%.

Peers: The peers of Trident Texofab are Bang Overseas, Parmeshwari Silk, Shekhawati Inds, Shubham Polyspin, Vinny Overseas, SVP Global, Gujarat Cotex, and Nandani Creation.<BR><BR>Quality Snapshot: Below Average management risk is observed at Bang Overseas, Shubham Polyspin, Vinny Overseas, SVP Global, Gujarat Cotex, and Trident Texofab, while Average management risk is found at Parmeshwari Silk, Shekhawati Inds, and Nandani Creation. Good growth is noted at Bang Overseas and Nandani Creation, while Below Average growth is seen at Trident Texofab, Parmeshwari Silk, Shekhawati Inds, Shubham Polyspin, Vinny Overseas, SVP Global, and Gujarat Cotex. The Capital Structure is rated Below Average for Bang Overseas, Trident Texofab, Shubham Polyspin, Vinny Overseas, SVP Global, Gujarat Cotex, and Nandani Creation, while Parmeshwari Silk and Shekhawati Inds have an Average rating.<BR><BR>Return Snapshot: Parmeshwari Silk has the highest 1-year return at 622.42%, while Trident Texofab has the lowest at -81.70%, indicating a significant negative performance compared to its peers. Additionally, Bang Overseas, Shekhawati Inds, Shubham Polyspin, Vinny Overseas, SVP Global, Gujarat Cotex, and Trident Texofab all report negative six-month returns.

Should I buy, sell or hold Trident Texofab Ltd?

Are Trident Texofab Ltd latest results good or bad?

Trident Texofab Ltd's latest results are concerning, showing a 12.14% year-on-year revenue decline and a net loss of ₹2.01 crores, leading to a "Strong Sell" recommendation due to negative operating margins and operational challenges.

Trident Texofab Ltd's latest results indicate a troubling performance. For the quarter ending March 2026, the company reported a revenue decline of 12.14% year-on-year, totaling ₹33.57 crores, despite a sequential improvement of 30.42% from the previous quarter. More concerning is the company's slip into operating losses, with an operating profit margin of -3.25%, a significant drop from the 3.56% margin achieved in the same quarter last year.<BR><BR>The net profit for this quarter was a loss of ₹2.01 crores, compared to a profit of ₹0.51 crores in the prior year, marking a drastic reversal in earnings. This decline raises serious concerns about the company's competitive positioning and cost structure, especially given the typically strong demand in the textile sector during this period.<BR><BR>Overall, the results reflect significant operational challenges and a deterioration in financial health, leading to a "Strong Sell" recommendation for investors. The company faces multiple red flags, including negative operating margins and weak capital efficiency, which overshadow any potential positives from sequential revenue recovery.

When is the next results date for Trident Texofab Ltd?

The next results date for Trident Texofab Ltd is 28 May 2026.

The next results date for Trident Texofab Ltd is scheduled for 28 May 2026.

Is Trident Texofab overvalued or undervalued?

As of December 4, 2025, Trident Texofab is considered very expensive with a PE ratio of 171.99 and significantly higher valuation metrics compared to its peers, indicating that its impressive stock performance may not be justified by its fundamentals.

As of 4 December 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 171.99, an EV to EBITDA of 65.76, and a PEG ratio of 18.66, all of which are considerably higher than industry norms. <BR><BR>In comparison to its peers, Elitecon International has a PE ratio of 197.4, while Lloyds Enterprises stands at 24.29, highlighting the stark contrast in valuation metrics within the sector. Despite Trident Texofab's impressive stock performance, with a year-to-date return of 102.05% compared to the Sensex's 9.12%, the current valuation suggests that investors may be paying a premium that is not justified by the company's fundamentals.

Is Trident Texofab technically bullish or bearish?

As of December 3, 2025, the trend is mildly bullish, supported by daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish weekly MACD and bearish monthly RSI.

As of 3 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a mildly bullish trend on both weekly and monthly time frames. However, the weekly MACD is mildly bearish and the monthly RSI is bearish, which suggests some caution. The KST remains bullish on both weekly and monthly charts, providing some support to the mildly bullish outlook. Overall, while there are mixed signals, the prevailing trend is mildly bullish.

How has been the historical performance of Trident Texofab?

Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with profits also rising significantly. However, cash flow from operating activities turned negative in Mar'25, indicating challenges in cash management despite overall financial growth.

Answer:<BR>The historical performance of Trident Texofab shows a steady increase in net sales and overall financial growth over the years.<BR><BR>Breakdown:<BR>Trident Texofab's net sales have shown a consistent upward trend, rising from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25. Total operating income followed a similar pattern, reaching 122.06 Cr in Mar'25, up from 90.96 Cr in Mar'20. The company's total expenditure, excluding depreciation, also increased, amounting to 116.58 Cr in Mar'25, compared to 47.05 Cr in Mar'21. Operating profit (PBDIT) has fluctuated, peaking at 8.78 Cr in Mar'25, while profit before tax reached 2.58 Cr in the same year. Profit after tax has also improved, standing at 2.51 Cr in Mar'25, up from 0.35 Cr in Mar'21. The company's total assets grew significantly from 55.68 Cr in Mar'20 to 100.58 Cr in Mar'25, while total liabilities increased from 20.37 Cr to 26.50 Cr during the same period. Cash flow from operating activities turned negative in Mar'25 at -13.00 Cr, contrasting with positive cash flows in previous years. Overall, Trident Texofab has demonstrated growth in sales and profits, despite some challenges in cash flow management.

Who are the top shareholders of the Trident Texofab?

The top shareholder of Trident Texofab is promoter Hardik Jigishkumar Desai with 14.15%, followed by public shareholder Savitriben Mahendrabhai Shah at 1.44%. Individual investors collectively hold 59.36%, with no institutional or pledged promoter holdings.

The top shareholders of Trident Texofab include Hardik Jigishkumar Desai, who is the promoter with the highest holding at 14.15%. The highest public shareholder is Savitriben Mahendrabhai Shah, holding 1.44%. Additionally, individual investors collectively hold a significant portion of 59.36%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

What is the bonus history of the Trident Texofab?

Trident Texofab issued a bonus on August 11, 2020, in the ratio of 14:10, granting shareholders 14 additional shares for every 10 shares held, with a record date of August 12, 2020.

Trident Texofab has a bonus history that includes a notable issue on August 11, 2020. The company announced a bonus in the ratio of 14:10, meaning that for every 10 shares held, shareholders received an additional 14 shares. The record date for this bonus was August 12, 2020. If you have any more questions about Trident Texofab or need further details, feel free to ask!

Has Trident Texofab declared dividend?

Yes, Trident Texofab Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 18, 2019. However, the dividend yield is 0%, as there have been no dividend returns in recent periods, despite strong price returns.

Trident Texofab Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 18 Jul 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 Months period, the price return was 57.14%, the dividend return was 0%, resulting in a total return of 57.14%.<BR><BR>In the 1 Year period, the price return was 356.13%, the dividend return was 0%, resulting in a total return of 356.13%.<BR><BR>In the 2 Years period, the price return was 234.83%, the dividend return was 0%, resulting in a total return of 234.83%.<BR><BR>In the 3 Years period, the price return was 101.25%, the dividend return was 0%, resulting in a total return of 101.25%.<BR><BR>In the 4 Years period, the price return was 460.32%, the dividend return was 0%, resulting in a total return of 460.32%.<BR><BR>In the 5 Years period, the price return was 545.26%, the dividend return was 0%, resulting in a total return of 545.26%.<BR><BR>Overall, Trident Texofab has declared a dividend, but it has not contributed to any yield in recent periods, as indicated by the 0% dividend yield. The company has shown strong price returns across all periods, suggesting robust performance despite the lack of ongoing dividends.